- Home
- SRRK vs PRCT Comparison
SRRK vs PRCT Comparison
Compare SRRK & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRRK
- PRCT
- Stock Information
- Founded
- SRRK 2012
- PRCT 2009
- Country
- SRRK United States
- PRCT United States
- Employees
- SRRK N/A
- PRCT N/A
- Industry
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- PRCT Medical Specialities
- Sector
- SRRK Health Care
- PRCT Health Care
- Exchange
- SRRK Nasdaq
- PRCT Nasdaq
- Market Cap
- SRRK 2.8B
- PRCT 3.2B
- IPO Year
- SRRK 2018
- PRCT 2021
- Fundamental
- Price
- SRRK $29.06
- PRCT $56.86
- Analyst Decision
- SRRK Strong Buy
- PRCT Strong Buy
- Analyst Count
- SRRK 6
- PRCT 7
- Target Price
- SRRK $42.17
- PRCT $90.00
- AVG Volume (30 Days)
- SRRK 1.1M
- PRCT 850.8K
- Earning Date
- SRRK 05-14-2025
- PRCT 04-24-2025
- Dividend Yield
- SRRK N/A
- PRCT N/A
- EPS Growth
- SRRK N/A
- PRCT N/A
- EPS
- SRRK N/A
- PRCT N/A
- Revenue
- SRRK N/A
- PRCT $249,121,000.00
- Revenue This Year
- SRRK N/A
- PRCT $47.40
- Revenue Next Year
- SRRK $452.64
- PRCT $31.81
- P/E Ratio
- SRRK N/A
- PRCT N/A
- Revenue Growth
- SRRK N/A
- PRCT 59.36
- 52 Week Low
- SRRK $6.76
- PRCT $47.04
- 52 Week High
- SRRK $46.98
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- SRRK 42.92
- PRCT 50.98
- Support Level
- SRRK $28.29
- PRCT $54.72
- Resistance Level
- SRRK $31.60
- PRCT $59.19
- Average True Range (ATR)
- SRRK 1.53
- PRCT 2.57
- MACD
- SRRK -0.17
- PRCT 0.06
- Stochastic Oscillator
- SRRK 14.49
- PRCT 61.64
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.